Results 1 to 10 of about 8,451 (198)
Mepolizumab reduces systemic corticosteroid-related toxicities and healthcare burden in patients with eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome: a retrospective database study [PDF]
Frontiers in AllergyBackgroundSystemic corticosteroids (SCS) remain the cornerstone of eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) therapy but are associated with substantial toxicity. Mepolizumab, an anti-interleukin-5 biologic,
Thanai Pongdee +8 more
doaj +2 more sources
Mepolizumab initiation by day 30 and glucocorticoid exposure in newly diagnosed EGPA: a single-center 30-day landmark cohort study [PDF]
BMC Pulmonary MedicineBackground Evidence on mepolizumab soon after glucocorticoid initiation in newly diagnosed eosinophilic granulomatosis with polyangiitis (EGPA) is limited. We compared nonrandomized initial treatment strategies defined by mepolizumab initiation within 30
Shota Kaburaki +6 more
doaj +2 more sources
Frontiers in Pharmacology, 2023 Background: Mepolizumab has been approved by the FDA for add-on maintenance treatment of severe asthma with an eosinophilic phenotype. Real-world studies on mepolizumab-associated adverse events are limited. The present study aimed to explore mepolizumab-
Huqun Li +3 more
doaj +1 more source
Hospital Pharmacy, 2016 Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Cada, Dennis J +2 more
openaire +3 more sources
Respirology Case Reports, 2023 Mepolizumab, a humanized anti‐IL‐5 monoclonal antibody used for severe asthma, results in a reduced rate of asthma exacerbation, improved lung function, reduced oral corticosteroid use, and improved quality of life.
Takahiro Matsuyama +9 more
doaj +1 more source
Allergy, Asthma & Clinical Immunology, 2023 Background The mainstay of treatment for eosinophilic granulomatosis with polyangiitis (EGPA) is systemic corticosteroid therapy; some patients also receive intravenous immunoglobulins, other immunosuppressive agents, and biologics.
Nami Masumoto +7 more
doaj +1 more source
Frontiers in Pharmacology, 2023 Oral corticosteroids (OCS) are commonly used for the acute management of severe asthma exacerbations or as maintenance therapy; however, chronic use is associated with significant toxicities, e.g., osteoporosis. In the REal worlD Effectiveness and Safety
Christian Domingo +10 more
doaj +1 more source
Biomedicines, 2022 Severe asthma (SA) is categorized into multiple overlapping phenotypes and clinical characteristics driven by complex mechanistic inflammatory pathways. Mepolizumab is a human monoclonal antibody effectively targeting interleukin-5 in severe eosinophilic
Ruperto González-Pérez +3 more
doaj +1 more source
Health Sciences Review, 2023 Background: Recently, mepolizumab and benralizumab have been approved for the treatment of severe eosinophilic asthma. Objective: Thus, the main objective of the current study was to find out the exact efficacy and safety profile of mepolizumab and ...
Noor Alam, S. Latha, Anoop Kumar
doaj +1 more source
Use of Mepolizumab in Children and Adolescents with Asthma in the USA
Journal of Respiration, 2022 Introduction: Pediatric asthma affects 5.5 million US children and is the leading cause of pediatric chronic illness globally. Those with severe asthma have significantly higher healthcare costs compared to those with non-severe disease.
Jaclyn Davis +11 more
doaj +1 more source